clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Tenosynovitis D013717 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Ramzy I et al. GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. 2016 Rev. Inst. Med. Trop. Sao Paulo pmid:27982354
Gbinigie II and Lasserson D Clarithromycin-induced akathisia: a class effect of macrolides? 2016 BMJ Case Rep pmid:27927708
Miftahussurur M et al. Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. 2016 PLoS ONE pmid:27906990
Velu PP et al. Pulmonary Mycobacterium marinum infection: 'fish tank granuloma' of the lung. 2016 Scott Med J pmid:27872397
Noh HM et al. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice. 2016 Korean J Gastroenterol pmid:27871162
Yazdanbakhsh AR et al. Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes. 2016 Water Environ. Res. pmid:28661328
Sancak S et al. Intestinal blood flow by Doppler ultrasound: the impact of clarithromycin treatment for feeding intolerance in preterm neonates. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26135789
Matsumoto H et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. 2016 Dig. Dis. Sci. pmid:27659671
Kasai C et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. 2016 BMC Gastroenterol pmid:27716077
Gisbert JP Helicobacter pylori-related diseases. 2016 Gastroenterol Hepatol pmid:27888863
Noda H et al. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. 2016 J Gastrointestin Liver Dis pmid:27689190
Giorgio F et al. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. 2016 Scand. J. Gastroenterol. pmid:27687850
Donzelli A Helicobacter pylori Eradication? 2016 Gastroenterology pmid:27590693
Sanches BS et al. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. 2016 World J. Gastroenterol. pmid:27672279
Ohe M et al. A case of lupus nephritis treated with clarithromycin, tacrolimus, and glucocorticoids. 2016 Kaohsiung J. Med. Sci. pmid:27638410
Rossi A et al. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. 2016 Drug Dev Ind Pharm pmid:26065531
Cosme A et al. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. 2016 Helicobacter pmid:25982426
Harada T et al. Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. 2016 J. Pharmacol. Exp. Ther. pmid:27489022
Bonfigli AR et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. 2016 Nutr Metab Cardiovasc Dis pmid:27480449
Orrin E et al. Sporotrichoid Mycobacterium chelonae. 2016 Australas. J. Dermatol. pmid:27469486
Yamamoto K et al. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. 2016 Pharmacol. Res. pmid:27468646
Ferro BE et al. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. 2016 Antimicrob. Agents Chemother. pmid:27458221
Patton PH et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. 2016 Cochrane Database Syst Rev pmid:27444319
Christl I et al. Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. 2016 Environ. Sci. Technol. pmid:27438991
Luo XF et al. Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. 2016 World J. Gastroenterol. pmid:27433095
Sakurai Y et al. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. 2016 Adv Ther pmid:27432383
Inagaki K et al. Successful Treatment of Peritoneal Dialysis-related Peritonitis due to Mycobacterium iranicum. 2016 Intern. Med. pmid:27432106
Shiratori S et al. Two Cases of Chronic Gastritis with non-Helicobacter pylori Helicobacter Infection. 2016 Intern. Med. pmid:27432094
Furuta K et al. 18 Cases of pulmonary Mycobacterium abscessus: Clinical difference depending on the presence or absence of Mycobacterium avium complex. 2016 J. Infect. Chemother. pmid:27430867
Zemali N et al. Helicobacter pylori resistance to clarithromycin in Reunion Island. 2016 Med Mal Infect pmid:27427280
Ozeki K et al. Association of Hay Fever with the Failure of Helicobacter pylori Primary Eradication. 2016 Intern. Med. pmid:27374672
Campillo A et al. [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. 2016 Med Clin (Barc) pmid:27374029
Khashei R et al. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. 2016 APMIS pmid:27357065
Hirasawa K et al. Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. 2016 PLoS ONE pmid:27977675
Mougari F et al. Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. 2016 Expert Rev Anti Infect Ther pmid:27690688
Ullah S et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. 2016 Drug Deliv pmid:27247018
Kuo CH et al. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. 2016 Medicine (Baltimore) pmid:27227911
Sluch IM et al. Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. 2016 Cornea pmid:27227391
Laird-Fick HS et al. Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. 2016 Postgrad Med J pmid:27222587
Phiphatpatthamaamphan K et al. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. 2016 Asian Pac. J. Cancer Prev. pmid:27221874
Kim SY et al. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. 2016 BMC Infect. Dis. pmid:27188784
Suzuki S et al. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. 2016 Am. J. Gastroenterol. pmid:27185079
Garcia de Carvalho NF et al. Resazurin Microtiter Assay for Clarithromycin Susceptibility Testing of Clinical Isolates of Mycobacterium abscessus Group. 2016 J. Clin. Lab. Anal. pmid:27169515
Xu J et al. Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. 2016 Eur J Drug Metab Pharmacokinet pmid:25652786
Schuster S et al. Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB. 2016 Antimicrob. Agents Chemother. pmid:27161641
Oberhofer E [Quadruple therapy is more effective against H. pylori]. 2016 MMW Fortschr Med pmid:27155683
Mayor S Short term increase in neuropsychiatric events is seen with H pylori treatment containing clarithromycin. 2016 BMJ pmid:27143325
Li M et al. Inducible Expression of both ermB and ermT Conferred High Macrolide Resistance in Streptococcus gallolyticus subsp. pasteurianus Isolates in China. 2016 Int J Mol Sci pmid:27669217
Tsaganos T et al. Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. 2016 Antimicrob. Agents Chemother. pmid:27044546
Buchicchio A et al. Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). 2016 Sci. Total Environ. pmid:27039063
Melia MT and Auwaerter PG Time for a Different Approach to Lyme Disease and Long-Term Symptoms. 2016 N. Engl. J. Med. pmid:27028918
Berende A et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. 2016 N. Engl. J. Med. pmid:27028911
D'Erme AM et al. Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. 2016 Int. J. Dermatol. pmid:27028670
Klesiewicz K et al. Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. 2016 J. Antibiot. pmid:27025351
Kawashima K et al. Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. 2016 Dig Liver Dis pmid:27012448
Ormeci A et al. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole. 2016 Eur Rev Med Pharmacol Sci pmid:27010145
Dubini M et al. Multiple drug allergy: A case of anaphylaxis to levofloxacin but tolerance to ciprofloxacin. 2016 Ann. Allergy Asthma Immunol. pmid:27009438
Miyashita N et al. Macrolide Therapy for Prevention of Exacerbation in Individuals with Diffuse Aspiration Bronchiolitis. 2016 J Am Geriatr Soc pmid:27000351
Shichijo S et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. 2016 Gastrointest. Endosc. pmid:26995689
Radzikowska E et al. Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment. 2016 Adv. Exp. Med. Biol. pmid:26987326
Wu DC et al. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. 2016 Medicine (Baltimore) pmid:26986096
Belz D et al. Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. 2016 J Eur Acad Dermatol Venereol pmid:25510444
Swaminathan A et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. 2016 Int. J. Tuberc. Lung Dis. pmid:26970156
Wong IC Author's reply to Blake. 2016 BMJ pmid:26957514
Todo K et al. Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female. 2016 Ann. Hematol. pmid:26957356
Tepeš B et al. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. 2016 Eur J Gastroenterol Hepatol pmid:26862930
Lim SG et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. 2016 Dig Liver Dis pmid:26856963
Niv Y Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. 2016 Digestion pmid:26849820
Song Z et al. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. 2016 Dig Liver Dis pmid:26847964
Vannarath S et al. Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. 2016 Asian Pac. J. Cancer Prev. pmid:26838225
Miyamoto S et al. Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. 2016 Tumour Biol. pmid:26825980
Bohnert JA et al. Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. 2016 Antimicrob. Agents Chemother. pmid:26824939
Kadota T et al. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. 2016 BMC Infect. Dis. pmid:26818764
Gaüzère BA and Malvy D [Vingt-cinquième réunion du comité local de la Société de pathologie exotique, 24 novembre 2015]. 2016 Bull Soc Pathol Exot pmid:26818816
Tebruegge M et al. Nontuberculous Mycobacterial Disease in Children - Epidemiology, Diagnosis & Management at a Tertiary Center. 2016 PLoS ONE pmid:26812154
Fralick M et al. Bleeding associated with coadministration of rivaroxaban and clarithromycin. 2016 CMAJ pmid:26811362
Berlin S et al. Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals. 2016 Mol. Pharm. pmid:26808255
Sun H et al. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014]. 2016 Zhonghua Jie He He Hu Xi Za Zhi pmid:26792053
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Topp E et al. Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. 2016 Sci. Total Environ. pmid:27096634
Li X et al. Macrolides use and the risk of sudden cardiac death. 2016 Expert Rev Anti Infect Ther pmid:27086751
Konstantinidis T et al. Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. 2016 Antimicrob. Agents Chemother. pmid:26643338
Ferro BE et al. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. 2016 Antimicrob. Agents Chemother. pmid:26643335
Boyanova L et al. Clarithromycin Resistance Mutations in Helicobacter pylori in Association with Virulence Factors and Antibiotic Susceptibility of the Strains. 2016 Microb. Drug Resist. pmid:26618567
Villain J et al. Acute toxicities of pharmaceuticals toward green algae. mode of action, biopharmaceutical drug disposition classification system and quantile regression models. 2016 Ecotoxicol. Environ. Saf. pmid:26590695
Geng S et al. Clarithromycin ion pair in a liposomal membrane to improve its stability and reduce its irritation caused by intravenous administration. 2016 Expert Opin Drug Deliv pmid:26588710
Wu TS et al. Postcesarean section wound infection caused by Mycobacterium massiliense. 2016 J Microbiol Immunol Infect pmid:26350122
Eszik I et al. High dynamic range detection of Chlamydia trachomatis growth by direct quantitative PCR of the infected cells. 2016 J. Microbiol. Methods pmid:26578244
Jain SK et al. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori. 2016 AAPS PharmSciTech pmid:26566630
Chen CH et al. Mycobacterium abscessus complex bacteremia due to prostatitis after prostate biopsy. 2016 Indian J Tuberc pmid:27998503
Qiu XH et al. Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. 2016 Acta Haematol. pmid:26505646
Senatore FJ et al. Helicobacter pylori treatment: Still a work in progress. 2016 Postgrad Med pmid:26490697
Shin WG et al. Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. 2016 Helicobacter pmid:26470999
Cerqueira RM et al. How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery? 2016 Obes Surg pmid:26467690
Boyanova L et al. Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. 2016 Infect Dis (Lond) pmid:26465202
Lahmer T et al. Pseudallescheria boydii with Aspergillus fumigatus and Aspergillus terreus in a Critically Ill Hematopoietic Stem Cell Recipient with ARDS. 2016 Mycopathologia pmid:26455910
Narita M et al. Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. 2016 Bull. Tokyo Dent. Coll. pmid:27665691
Ghaith D et al. Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. 2016 J Chemother pmid:26358218
Yoon H et al. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. 2016 Gut Liver pmid:26347514
Liou JM et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. 2016 Gut pmid:26338825